321 related articles for article (PubMed ID: 15455033)
1. Developmental context determines latency of MYC-induced tumorigenesis.
Beer S; Zetterberg A; Ihrie RA; McTaggart RA; Yang Q; Bradon N; Arvanitis C; Attardi LD; Feng S; Ruebner B; Cardiff RD; Felsher DW
PLoS Biol; 2004 Nov; 2(11):e332. PubMed ID: 15455033
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of AP-1 transcription activator induces myc-dependent apoptosis in HL60 cells.
Park S; Hahm ER; Lee DK; Yang CH
J Cell Biochem; 2004 Apr; 91(5):973-86. PubMed ID: 15034932
[TBL] [Abstract][Full Text] [Related]
3. Distinct thresholds govern Myc's biological output in vivo.
Murphy DJ; Junttila MR; Pouyet L; Karnezis A; Shchors K; Bui DA; Brown-Swigart L; Johnson L; Evan GI
Cancer Cell; 2008 Dec; 14(6):447-57. PubMed ID: 19061836
[TBL] [Abstract][Full Text] [Related]
4. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
5. Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation.
Amicone L; Terradillos O; Calvo L; Costabile B; Cicchini C; Della Rocca C; Lozupone F; Piacentini M; Buendia MA; Tripodi M
Oncogene; 2002 Feb; 21(9):1335-45. PubMed ID: 11857077
[TBL] [Abstract][Full Text] [Related]
6. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
7. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.
Valsesia-Wittmann S; Magdeleine M; Dupasquier S; Garin E; Jallas AC; Combaret V; Krause A; Leissner P; Puisieux A
Cancer Cell; 2004 Dec; 6(6):625-30. PubMed ID: 15607966
[TBL] [Abstract][Full Text] [Related]
9. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
Conner EA; Lemmer ER; Omori M; Wirth PJ; Factor VM; Thorgeirsson SS
Oncogene; 2000 Oct; 19(44):5054-62. PubMed ID: 11042693
[TBL] [Abstract][Full Text] [Related]
10. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.
Santoni-Rugiu E; Nagy P; Jensen MR; Factor VM; Thorgeirsson SS
Am J Pathol; 1996 Aug; 149(2):407-28. PubMed ID: 8701981
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal location targets different MYC family gene members for oncogenic translocations.
Gostissa M; Ranganath S; Bianco JM; Alt FW
Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2265-70. PubMed ID: 19174520
[TBL] [Abstract][Full Text] [Related]
13. Myc lacks E2F1's ability to suppress skin carcinogenesis.
Rounbehler RJ; Schneider-Broussard R; Conti CJ; Johnson DG
Oncogene; 2001 Aug; 20(38):5341-9. PubMed ID: 11536046
[TBL] [Abstract][Full Text] [Related]
14. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis.
Amundadottir LT; Nass SJ; Berchem GJ; Johnson MD; Dickson RB
Oncogene; 1996 Aug; 13(4):757-65. PubMed ID: 8761297
[TBL] [Abstract][Full Text] [Related]
15. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
16. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation.
Chen H; Liu J; Zhao CQ; Diwan BA; Merrick BA; Waalkes MP
Toxicol Appl Pharmacol; 2001 Sep; 175(3):260-8. PubMed ID: 11559025
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis.
Beer S; Komatsubara K; Bellovin DI; Kurobe M; Sylvester K; Felsher DW
PLoS One; 2008 Jun; 3(6):e2493. PubMed ID: 18560566
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
19. Developmental stage determines the effects of MYC in the mammary epithelium.
Blakely CM; Sintasath L; D'Cruz CM; Hahn KT; Dugan KD; Belka GK; Chodosh LA
Development; 2005 Mar; 132(5):1147-60. PubMed ID: 15689376
[TBL] [Abstract][Full Text] [Related]
20. Differential cooperation of oncogenes with p53 and Bax to induce apoptosis in rhabdomyosarcoma.
Taylor AC; Schuster K; McKenzie PP; Harris LC
Mol Cancer; 2006 Nov; 5():53. PubMed ID: 17081294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
